Tenax Therapeutics (TENX) to Release Earnings on Thursday

Tenax Therapeutics (NASDAQ:TENX) is expected to be issuing its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.51) per share for the quarter.

Tenax Therapeutics Price Performance

Shares of TENX stock opened at $6.43 on Thursday. Tenax Therapeutics has a 1 year low of $2.77 and a 1 year high of $7.89. The firm has a fifty day moving average price of $6.44 and a 200-day moving average price of $5.30.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on TENX shares. William Blair reissued an “outperform” rating on shares of Tenax Therapeutics in a research report on Monday, March 10th. Leerink Partners set a $20.00 price objective on shares of Tenax Therapeutics in a research report on Monday, March 10th. Finally, StockNews.com started coverage on shares of Tenax Therapeutics in a research report on Thursday, March 13th. They set a “sell” rating for the company. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.